

August 7, 2018

To Whom It May Concern:

Company Name: KIRIN HOLDINGS COMPANY, LIMITED  
Name and Title of Representative: Yoshinori Isozaki, President & CEO  
Code Number: 2503  
Head Office: 4-10-2, Nakano, Nakano-ku, Tokyo 164-0001, Japan  
Name and Title of Contact Person:  
Tetsuya Fujiwara, Director of Group Corporate Communications  
Telephone Number: (03) 6837-7015

**(Updated) Notice of partial revision of the Supplementary Documents to the Consolidated Financial Statements for the Three Months Ended March 31, 2018 (under IFRS)**

Kirin Holdings Company, Limited today announced the following revisions of the Supplementary Documents to the Consolidated Financial Statements for the Three Months Ended March 31, 2018 (under IFRS) released on May 10, 2018 as listed below. The revised parts are underlined.

**1. The Revision**

Supplementary Documents to the Consolidated Financial Statements for the three Months Ended March 31, 2018

Page 16

3. Revenue Details (1) Revenue Details

<Before revision>

(¥ billions)

	Three months ended	Three months ended	Increase (decrease)	
	March 31, 2018, Actual	March 31, 2017, Actual		
Revenue	431.2	414.4	16.8	4.0%
Pharmaceuticals and Bio-chemicals	83.1	89.9	(6.8)	(7.5%)
Kyowa Hakko Kirin	<u>85.7</u>	<u>92.5</u>	<u>(6.8)</u>	<u>(7.3%)</u>
Pharmaceuticals	<u>66.5</u>	<u>72.3</u>	<u>(5.8)</u>	<u>(8.0%)</u>
Bio-chemicals	<u>19.2</u>	<u>20.2</u>	<u>(1.0)</u>	<u>(4.9%)</u>
Other and elimination	<u>(2.5)</u>	<u>(2.6)</u>	<u>(0.0)</u>	-

<After revision>

(¥ billions)

	Three months ended	Three months ended	Increase (decrease)	
	March 31, 2018, Actual	March 31, 2017, Actual		
Revenue	431.2	414.4	16.8	4.0%
Pharmaceuticals and Bio-chemicals	83.1	89.9	(6.8)	(7.5%)
Kyowa Hakko Kirin	<u>84.9</u>	<u>91.5</u>	<u>(6.6)</u>	<u>(7.2%)</u>
Pharmaceuticals	<u>66.2</u>	<u>72.1</u>	<u>(5.9)</u>	<u>(8.2%)</u>
Bio-chemicals	<u>18.7</u>	<u>19.4</u>	<u>(0.7)</u>	<u>(3.8%)</u>
Other and elimination	<u>(1.7)</u>	<u>(1.6)</u>	<u>(0.1)</u>	-

END